Clinical Application of Anti-CCR4 Monoclonal Antibody

@article{Ueda2015ClinicalAO,
  title={Clinical Application of Anti-CCR4 Monoclonal Antibody},
  author={Ryuzo Ueda},
  journal={Oncology},
  year={2015},
  volume={89},
  pages={16 - 21}
}
  • R. Ueda
  • Published 1 November 2015
  • Medicine
  • Oncology
Mogamulizumab (KW-0761) is a humanized anti-CCR4 monoclonal antibody with a defucosylated Fc region (Potelligent® Technology), which markedly enhances antibody-dependent cellular cytotoxicity by increasing its binding affinity to the Fcγ receptor expressed on effector cells. It is an effective agent for patients with CCR4-positive adult T-cell leukemia and peripheral T-cell lymphoma, for which no standard therapy exists, and it has an acceptable toxicity profile. In addition, because CCR4 is… 
CCR4 as a Therapeutic Target for Cancer Immunotherapy
TLDR
This review overviews the expression of CCR4 in various T cell subsets, HTLV-1-infected T cells, ATLL and CTCLs, and the clinical applications of Mogamulizumab, and examines its significance as a therapeutic target in cancer immunotherapy.
Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness
TLDR
The studies show that the combination of CTX and GITR agonism is a rational chemoimmunotherapeutic approach that warrants further clinical investigation, and causes tumor cell death, clonal expansion of highly active CD8+ T cells, and depletion of Tregs by activation-induced cell death.
Development of anti-human CADM1 monoclonal antibodies as a potential therapy for adult T-cell leukemia/lymphoma
TLDR
In mice bearing intra-splenic transplantation of EL4 mouse lymphoma cells expressing CADM1, the treatment of 103–189 significantly suppressed the organ invasion of CADM 1-positive EL4 cells, resulting in improved survival time of mice.
Immune suppression and reversal of the suppressive tumor microenvironment
TLDR
The mechanisms by which tumors exert immune suppression as well as their regulation are reviewed, and how the complex reciprocal interactions between immunosuppressive and immunostimulatory cells influence immune cell dynamics in the TME is discussed.
Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells
TLDR
The classification, immunosuppressive mechanisms, existing immunotherapies, and potential biomarkers related to tumor-infiltrating Tregs are summarized to guide the development of effective cancer immunotherAPies.
Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma.
TLDR
Overall, the findings offered a preclinical proof of concept for the potential use of CCL22 delivered by local injection as a strategy to enhance the efficacious response to immune checkpoint therapy while suppressing its autoimmune side effects.
CCR4 Blockade Depletes Regulatory T Cells and Prolongs Survival in a Canine Model of Bladder Cancer
Anti-CCR4 treatment to target regulatory T cells induced clinical responses and prolonged survival in dogs with spontaneous bladder cancer. Expression of CCR4 in human tumor samples suggests
Immuno-oncology combinations: raising the tail of the survival curve
TLDR
The biology underpinning immuno-oncology is reviewed, existing and novel immunotherapeutic combinations currently in development, the challenges of predictive biomarkers of response and resistance and the impact of Immuno- oncology on early phase clinical trial design are discussed.
Regulatory T Cells in the Tumor Microenvironment.
TLDR
This chapter will discuss the history and hallmarks of Tregs, the recruitment, development, and persistence of T Regs within the TME; Treg function within TME, as well as the therapeutic targeting of TRegs in the clinic.
Emerging therapeutic agents for genitourinary cancers
TLDR
Many of the promising new emerging therapies that will likely continue to improve outcomes in patients with genitourinary malignancies are highlighted.
...
1
2
3
4
...

References

SHOWING 1-10 OF 29 REFERENCES
Immunopathogenesis of lymphoma: Focus on CCR4
TLDR
A defucosylated anti‐CCR4 mAb is developed, the first therapeutic agent targeting CCR4 to be used clinically for cancer, and could be used as a novel treatment strategy for many types of C CR4− cancers to overcome the suppressive effect of CCR 4+ Treg cells.
Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.
  • T. Ishida, T. Joh, +17 authors R. Ueda
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
TLDR
KW-0761 demonstrated clinically meaningful antitumor activity in patients with relapsed ATL, with an acceptable toxicity profile, and further investigation of KW-761 for treatment of ATL and other T-cell neoplasms is warranted.
Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/Lymphoma
TLDR
Whether the antitumor activity of KW-0761 would likely be sufficient for therapeutic clinical application against ATLL and the mechanism of antibody-dependent cellular cytotoxicity mediated by this defucosylated monoclonal antibody is investigated.
Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
TLDR
KW-0761 was tolerated at all the dose levels tested, demonstrating potential efficacy against relapsed CCR4-positive ATL or PTCL, and subsequent phase II studies at the 1.0 mg/kg dose are thus warranted.
Defucosylated Anti-CCR4 Monoclonal Antibody Exerts Potent ADCC against Primary ATLL Cells Mediated by Autologous Human Immune Cells in NOD/Shi-scid, IL-2Rγnull Mice In Vivo1
TLDR
This study is the first to report a mouse model in which a potent antitumor effect of the therapeutic mAb against primary tumor cells is mediated by autologous human immune cells, and defucosylated anti-CCR4 mAb is used to enhance ADCC.
CCR4 as a novel molecular target for immunotherapy of cancer
TLDR
A novel humanized anti‐CCR4 monoclonal antibody (mAb) has been developed, the Fc region of which is defucosylated to enhance antibody‐dependent cellular cytotoxicity by increasing its binding affinity to Fc receptor on effector cells.
The CC Chemokine Receptor 4 as a Novel Specific Molecular Target for Immunotherapy in Adult T-Cell Leukemia/Lymphoma
TLDR
The data suggest not only that the CCR4 molecule could be a suitable target for the novel antibody-based therapy for patients with ATLL but also that KM2760 may induce effective tumor immunity by reducing the number of regulatory T cells.
Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
  • M. Ogura, T. Ishida, +16 authors R. Ueda
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2014
TLDR
Mogamulizumab exhibited clinically meaningful antitumor activity in patients with relapsed PTCL and CTCL, with an acceptable toxicity profile, and further investigation of mogamulIZumab for treatment of T-cell lymphoma is warranted.
Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients
TLDR
Combined use of KW-0761 to deplete FoxP3+ Tregs with other immunotherapies, such as cancer vaccines or checkpoint inhibitors, is a promising approach to augment immune responses.
Defucosylated Chimeric Anti-CC Chemokine Receptor 4 IgG1 with Enhanced Antibody-Dependent Cellular Cytotoxicity Shows Potent Therapeutic Activity to T-Cell Leukemia and Lymphoma
TLDR
The results indicate that defucosylated antibodies with enhanced ADCC as well as potent antitumor activity in vivo are promising candidates for the novel antibody-based therapy.
...
1
2
3
...